TICKERNERD
Menu
PRLDPRLDHealthcare · Biotechnology

PRLD Stock Forecast: Prelude Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$4.10
−0.97% on the day

The 5 Wall Street analysts covering Prelude Therapeutics, Inc. hold a median 12-month price target of $10 — +143.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 28 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$309.0M
Ticker Nerd rank
91/ 100
Median analyst target
$10
Analysts covering
5
Revenue$5.7M
Operating income−$15.5M
Net income−$13.9M
Free cash flow−$15.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+13.9%
1M
+3.5%
YTD
+41.4%
1Y
+159.5%
From 52W high
−38.2%
From 52W low
+244.5%
$1.19
$6.63
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRLD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Prelude Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
91/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
96
Momentum
91
Value
84
Accruals
78
Quality
68
Size
59
Revisions
58
Issuance
38
Volatility
38

Growth (96): Sales and profits are climbing, and climbing faster than before.

Volatility (38): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PRLD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRLD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26PRLDHigh $12Median $10Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $6Median $10High $12

The green dot is the last close — the median target sits +143.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
17 Sept 2026JP MorganInitiatesOverweight$12
29 July 2026HC Wainwright & Co.ReiteratesBuy$8.00
29 July 2026HC Wainwright & Co.ReiteratesBuy—
15 May 2026Goldman SachsInitiatesEarly-Stage Biotech—
4 May 2026D. Boral CapitalInitiatesBuy$9.00
4 May 2026D. Boral CapitalInitiatesBuy—
27 Apr 2026HC Wainwright & Co.MaintainsBuy$5.00 → $8.00
27 Apr 2026HC Wainwright & Co.MaintainsBuy—
11 Mar 2026CitizensMaintainsMarket Outperform—
23 Sept 2025HC Wainwright & Co.ReiteratesBuy—
18 Aug 2025JMP SecuritiesMaintainsMarket Outperform—
5 May 2025HC Wainwright & Co.ReiteratesBuy—
29 Apr 2025JMP SecuritiesReiteratesMarket Outperform—
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
12 Mar 2025Citizens Capital MarketsReiteratesMarket Outperform—
11 Dec 2024JMP SecuritiesReiteratesMarket Outperform—
8 Nov 2024HC Wainwright & Co.ReiteratesBuy—
28 Oct 2024HC Wainwright & Co.ReiteratesBuy—
19 Sept 2024HC Wainwright & Co.UpgradeBuy—
16 Sept 2024HC Wainwright & Co.ReiteratesNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PRLD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PRLD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 29 Oct 2026, Prelude Therapeutics, Inc. returned +159.5% against +13.6% for the S&P 500, dividends included.

PRLD vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Jan 26Apr 26Jul 26Oct 26PRLDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRLD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Prelude Therapeutics, Inc. (PRLD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−3.2×

Cheaper than 88% of US stocks

Price / sales
14.2×

Cheaper than 11% of US stocks

Price / book
3.1×

Cheaper than 30% of US stocks

EV / EBITDA
−4.1×

Cheaper than 79% of US stocks

Growth & margins
Revenue growth (YoY)
24.5%

Higher than 74% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−270.9%

Higher than 9% of US stocks

Net margin
−269.7%

Higher than 1% of US stocks

Returns & dividend
Return on equity
−57.7%

Higher than 20% of US stocks

Return on assets
−27.2%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Prelude Therapeutics, Inc. (PRLD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Prelude Therapeutics, Inc. has a market value of $309.0M and an enterprise value of $265.5M.

  • Revenue in the twelve months to 30 June 2026: $22.4M. The latest quarter grew 24.5% year on year.

  • Net income over the same four quarters: −$60.5M, a −269.7% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$33.3M.

  • Shares outstanding: 79.8M.

  • Trailing P/E: −3.2×; forward P/E: −6.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Prelude Therapeutics, Inc. employs 79 people — $284K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 28 Oct 2026

Data provided by Twelve Data

Peers

PRLD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PRLDPrelude Therapeutics, Inc.$309.0M91
SCTXScribe Therapeutics, Inc.$330.9M2
TTRXTurn Therapeutics, Inc.$327.4M22
XFORX4 Pharmaceuticals, Inc.$332.1M61
ALECAlector, Inc.$333.6M55
ENTAEnanta Pharmaceuticals, Inc.$336.4M91
AGENAgenus, Inc.$319.1M86

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Prelude Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRLD news & analysis

Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option

MarketBeat · 23 Oct 2026positive

Prelude Therapeutics outlined progress on three priority programs at a Chardan Capital investor session: its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer, and a mutant calreticulin program for myeloproliferative neoplasms. The headline also highlights a potential $100 million Incyte option.

Why it matters — The update gives PRLD watchers information on the company’s research pipeline and a potential Incyte-related option.

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

GlobeNewsWire · 16 Oct 2026neutral

Prelude Therapeutics announced that it will participate in the Chardan Healthcare Conference in New York City on October 20, 2026.

Why it matters — The announcement provides PRLD watchers with details of the company's upcoming conference participation.

Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround

Zacks Investment Research · 16 Oct 2026positive

Prelude Therapeutics is described as technically oversold after a 27.4% decline over four weeks. The article cites exhausted selling pressure and analyst earnings-estimate increases as factors that could contribute to a trend reversal.

Why it matters — PRLD watchers may note the article's oversold signal and analyst estimate revisions as potential indicators of a change in the stock's recent trend.

Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer

GlobeNewsWire · 13 Oct 2026positive

Prelude announced a clinical trial collaboration and supply agreement with Lilly to evaluate its KAT6A selective degrader PRT13722 in combination with Verzenio and Inluriyo in patients with HR+/HER2- breast cancer. The combination cohorts are part of Prelude’s Phase 1 trial, with enrollment on track to begin in the fourth quarter of 2026.

Why it matters — The agreement adds combination cohorts with Lilly medicines to Prelude’s planned Phase 1 evaluation of PRT13722 in HR+/HER2- breast cancer.

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 11 Sept 2026neutral

Prelude Therapeutics announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, scheduled for September 14-16, 2026, in New York City.

Why it matters — A PRLD watcher would care because the company's participation offers a platform for presenting its clinical-stage oncology pipeline to investors at a major industry conference.

FAQ

Frequently asked questions about PRLD stock

What is the PRLD stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Prelude Therapeutics, Inc. have a median 12-month price target of $10, with estimates ranging from $6 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRLD stock a buy right now?

Of the 5 analysts covering Prelude Therapeutics, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prelude Therapeutics, Inc. 91 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRLD?

As at 28 Oct 2026, Prelude Therapeutics, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (96 of 100).

Will PRLD stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +143.9% from the last close, and Ticker Nerd's factor model ranks Prelude Therapeutics, Inc. 91 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRLD stock forecast for 2030?

No analyst covering Prelude Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRLD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $12 over the next 12 months.

How has PRLD stock performed over the past year?

Prelude Therapeutics, Inc. returned +159.5% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Prelude Therapeutics, Inc. do?

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel medicines for cancer patients with high unmet medical needs. Prelude Therapeutics Incorporated is advancing a pipeline of targeted therapies designed to address genetically defined cancers and other difficult-to-treat tumors.

What is the latest news on PRLD?

The most recent item we track (MarketBeat, 23 Oct 2026): "Prelude Therapeutics Spotlights JAK2, KAT6A Programs and Potential $100M Incyte Option". Prelude Therapeutics outlined progress on three priority programs at a Chardan Capital investor session: its recently initiated JAK2 program, an IND-cleared KAT6A degrader for breast cancer, and a mutant calreticulin program for myeloproliferative neoplasms. The headline also highlights a potential $100 million Incyte option.

Company

About Prelude Therapeutics, Inc.

Prelude Therapeutics Incorporated is a clinical-stage precision oncology company focused on discovering and developing novel medicines for cancer patients with high unmet medical needs. Prelude Therapeutics Incorporated is advancing a pipeline of targeted therapies designed to address genetically defined cancers and other difficult-to-treat tumors. Its current programs include small-molecule candidates aimed at key cancer-driving mechanisms such as JAK2V617F, KAT6A, and SMARCA2, as well as approaches for myeloproliferative neoplasms, myelofibrosis, polycythemia vera, essential thrombocythemia, and breast cancer. The company’s work centers on precision medicine, using selective drug design to improve specificity against validated oncology targets. Prelude Therapeutics Incorporated operates as part of the biotechnology sector and plays a role in translating molecular biology insights into potential treatment options for underserved cancer populations.

CEO Dr. Krishna Vaddi D.V.M., Ph.D. · 79 employees · United States · https://preludetx.com